drugset

drugset / Trial / NCT06227221

Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus

NCT06227221 ↗

Phase 2 Not yet recruiting 10 enrolled Second Xiangya Hospital of Central South University

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the therapeutic effect and safety of Sorafenib in T1DM patients.

Timeline

Start: 2026-02
Primary completion: 2028-10
Completion: 2029-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sorafenib	Small molecule	400 mg	—

Indications